12 results about "Maternal blood" patented technology

A method of fetal genotyping, comprises receiving maternal genomic DNA (gDNA) data, maternal cell-free DNA (cfDNA) data, and paternal gDNA data of a pair parenting to a fetus. The data are analyzed to identify a first set of sites at which the parents are homozygous for different alleles, and a second set at which at least one of the parents has a mutation. For each site of the first set, a probability that a respective portion of the maternal cfDNA data is derived from the fetus is determined. Each site of the second set is classified according to the determined probabilities as being either fetal or maternal to genotype the fetus.

The present invention relates to storing and testing for abnormalities in cell free DNA (cfDNA) from blood, such as in maternal blood or blood for cancer screening.

The invention belongs to the technical field of obstetrics and gynecology disease prediction, and particularly relates to a premature fetal membrane premature rupture prediction marker based on maternal circulation exosome microRNA and an application kit. According to the invention, placentas, fetal membranes and plasma exosomes of pregnant women with full-term birth and premature birth premature rupture of fetal membranes are collected for sequencing, the fetal membrane-derived exosome hsa-miR-145-3p which can be detected in the plasma exosomes is screened out in combination with a verification set, and the cell source and the premature birth promoting effect of the fetal membrane-derived exosome hsa-miR-145-3p are respectively clarified at a cell level and an animal level; and finally, by detecting the level of the plasma exosome hsa-miR-145-3p of the pregnant 12 (+ 1)-17 (+ 6) perimaternal body, the efficiency (AUC = 0.833) of the exosome in predicting the occurrence of premature rupture of fetal membranes in premature delivery is illustrated. According to the method, the high-risk crowd of the pPROM can be predicted through a noninvasive method in the early and middle stages of pregnancy, and the method has guiding significance for subsequent prevention and intervention of the high-risk crowd.

The application discloses a labor fetal distress intelligent prediction method and system based on multi-modal data, relates to the technical field of intelligent medical treatment, and aims at the problem that existing single fetal heart monitoring is prone to false positive hypoxia false alarms due to the fact that painless delivery anesthesia induces transient hypotension of puerpera, the application synchronously acquires continuous fetal heart rate, uterine contraction, maternal noninvasive blood pressure and anesthesia pump injection drug data; multi-modal data is input into an artificial intelligence fusion model, anesthetic pharmacokinetic attenuation function is introduced as prior weight, cross attention network is used to extract the space-time implicit correlation features between hemodynamics and fetal heart changes; and then, cause contribution is calculated and dynamic threshold judgment is combined with maternal blood oxygen. The application effectively distinguishes drug compensation reaction from real pathological hypoxia, significantly reduces the false positive alarm rate, and avoids unnecessary emergency cesarean section intervention.

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

Disclosed is a method for assessing the age of a tissue, in particular the placenta, using circular RNAs. Further disclosed are methods for diagnosing or predicting the risk of a pregnancy complication, such as stillbirth, by quantifying circular RNAs in the placenta or a maternal blood sample.

The invention discloses a nutritional supplement for pregnant pets and a preparation method of the nutritional supplement. According to the preparation method, after chickpeas are hydrolyzed by protease, GAD enzyme and calcium chloride are added, glutamic acid is induced to be converted into GABA through calcium ions, and meanwhile free amino acid reacts with the calcium ions to generate amino acid chelated calcium; the egg yolk powder and the lactoferrin are utilized to construct a double-emulsion system, so that the GABA is protected from being damaged in advance, the amino acid chelated calcium is slowly released, and the absorption antagonism of mineral substances such as calcium, iron and zinc is reduced. The chicken breast, the chicken liver, the traditional Chinese medicines and other raw materials are chopped, mixed and sterilized to obtain a finished product. The nutritional powder is rich in GABA, soybean isoflavone, Omega-3 fatty acid, vitamin B6, lactoferrin, folic acid and various minerals, can directly or indirectly support progestational hormone secretion and relieve anxiety during pregnancy, meets the requirements of maternal blood replenishing and immunity improving and fetal development nutrition supply, and is suitable for nutrition supplement of pets during pregnancy.

The invention belongs to the technical field of medical instruments, and particularly relates to an amniotic fluid sampler for gynaecology and obstetrics, which comprises a puncture frame, an adsorber, a puncture outfit and a controller. The B-ultrasonic probe and the puncture needle are flexibly adjusted and fixed through the installer, and accurate positioning is ensured; the adsorber stably adsorbs the device to the abdomen of a patient through a negative pressure channel and a rubber air cushion, and displacement during operation is prevented; the puncture outfit adopts a specially designed puncture needle and comprises an outer sleeve and a rotatable sampling needle core, so that maternal blood or tissues are prevented from being carried, and the risk of sample pollution is reduced; the controller controls the driving motor through a needle feeding button and a needle withdrawing button, the puncturing depth and speed are automatically adjusted by combining a worm gear, a worm and a lead screw mechanism, and manual operation errors are reduced. According to the whole device, automatic control, stable fixing and clean sampling of amniotic fluid sampling are achieved through the structure, and the detection accuracy and operation convenience are improved.

A method for evaluating fetal DNA concentration (cffDNA) in maternal blood during pregnancy through polymorphic locus linkage block, comprising: obtaining low-depth WGS sequencing data of the sample; obtaining a mapping relationship between the locus and the linkage polymorphism; and calculating the concentration according to the low-depth WGS sequencing data and the mapping relationship between the locus and the linkage polymorphism and taking a plurality of loci constituting the linkage polymorphism as a unit. Wherein, the mapping relationship between the locus and the linkage polymorphism can be obtained by processing public genome WGS data, processing public linkage polymorphism block data or processing a large amount of high-depth WGS measured data. The present application is based on low-depth WGS data, and the heterozygosity of the linkage SNP block can be used to calculate the cffDNA concentration in the maternal blood during pregnancy, which is not affected by the fetal gender in the actual application of NIPT, does not require the father's sample and does not require additional experiments, has high stability, high performance and low cost.

The invention discloses an application of 3-IAA (3-indoleacetic acid) in preparation of a medicine for improving fetal adult osteoporosis. A fetal adult osteoporosis model is constructed according to the fact that the pregnancy dexamethasone exposure can cause the delayed development of offspring bone and the occurrence of adult osteoporosis, and it is found that the concentration of indole-3-acetic acid (3-IAA) in maternal blood and fetal blood exposed to dexamethasone in the pregnancy is reduced. Based on a rat model of adult offspring osteoporosis caused by pregnancy dexamethasone exposure, 20 mg / kg of 3-IAA is intragastrically fed to GD18-19. D, and the reduction of peak bone mass of female adult offspring caused by pregnancy dexamethasone exposure can be effectively reversed by 3-IAA. Therefore, the 3-IAA provides a new way for preventing and treating the fetal adult osteoporosis.

The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital analysis is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.

The present disclosure provides a non-invasive method for early diagnosis of a placental pathology comprising an abnormal formation or arrangement of a placenta in a uterus of a mammalian female subject during pregnancy. Early diagnosis can lead to an improved maternal outcome. The method comprises selectively purifying from plasma of maternal blood a population of small extracellular vesicles (small-EVs) expressing a placenta-specific surface biomarker. The extracellular vesicles comprise micro-RNA cargo. A cargo profile for the small EVs is determined by extracting RNA from the purified population of small EVs. Expression of small non-coding RNAs comprising one or more micro RNAs (miRNAs) encapsulated by the purified population of exosomes is then identified and quantified. The miRNA profile of the placenta specific EVs is then compared to the miRNA profile of a healthy control of the same approximate gestational age.